Journal article

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

Laura A Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z Wu, Simon Junankar, Aurelien A Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew MK Law, Andrea McFarland, Peter T Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger, Lyndal Anderson, Goli Samimi, Neville F Hacker, Elgene Lim Show all

Breast Cancer Research | BMC | Published : 2020


BACKGROUND: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. METHODS: Here, we have defined unique ..

View full abstract

University of Melbourne Researchers